Welcome to our dedicated page for BlossomHill Therapeutics SEC filings (Ticker: BLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BlossomHill Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BlossomHill Therapeutics's regulatory disclosures and financial reporting.
BlossomHill Therapeutics, Inc. (BLSM) insider group associated with Cormorant funds reported several equity changes. On August 10, 2026, Cormorant-related funds converted Series A and Series B Preferred Stock into an equal number of Common Stock shares in connection with the closing of the company’s initial public offering. The Master Fund also purchased 312,500 Common Stock shares at $16.00 per share, increasing its indirect position. Separately, on August 6, 2026, director and ten percent owner Bihua Chen received a stock option grant for 23,904 shares with a $16.00 exercise price, vesting monthly over three years and expiring on August 5, 2036. The reporting persons state that they may be deemed beneficial owners only to the extent of their pecuniary interest in the reported shares.
BlossomHill Therapeutics, Inc. (BLSM) reported that on August 10, 2026, 578,524 shares of Series B Preferred Stock held indirectly through Brahma BlossomHill Partners, LLC automatically converted into 578,524 shares of Common Stock upon the closing of BlossomHill Therapeutics’ initial public offering, with the preferred shares then reduced to zero. These securities are held of record by Brahma BlossomHill Partners, LLC, which is managed by an entity founded and led by director Sundeep Agrawal; he may be deemed to have voting or investment power but expressly disclaims beneficial ownership.
Separately, on August 6, 2026, Agrawal received a director stock option to purchase 23,904 shares of Common Stock at an exercise price of $16.00 per share, expiring on August 5, 2036. According to the vesting terms, 1/36 of the option shares vest in equal monthly installments over three years following August 6, 2026.
BlossomHill Therapeutics, Inc. (BLSM), a clinical-stage oncology-focused biopharmaceutical company, is conducting an initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share, for gross proceeds of $150.0 million before underwriting discounts. Underwriters have a 30‑day option to purchase up to 1,406,250 additional shares. Net proceeds to BlossomHill before expenses are expected to be $139.5 million, or $14.88 per share.
The company develops small‑molecule cancer therapies, led by BH‑30643, an OMNI‑EGFR inhibitor for EGFR‑mutant non‑small cell lung cancer in a Phase 1/2 trial, BH‑30236, a CLK inhibitor in a Phase 1 trial for relapsed/refractory AML and higher‑risk MDS, and BH‑501284, a preclinical pan‑KRAS inhibitor with IND filing planned in 2027. BlossomHill reported research and development expenses of $56.1 million and a net loss of $60.6 million in 2025, with an accumulated deficit of $156.0 million as of March 31, 2026.
Cash and cash equivalents were $116.0 million as of March 31, 2026, rising to a pro forma as‑adjusted $253.6 million after giving effect to the offering. The company’s auditors included a going concern explanatory paragraph, and BlossomHill states that even with IPO proceeds it will require substantial additional capital to complete development and potential commercialization of its pipeline. The common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “BLSM.”
BlossomHill Therapeutics, Inc. (BLSM) reported an initial insider ownership statement for director John P. Schmid. He holds a Director Stock Option covering 67,620 shares of common stock at an exercise price of $13.59 per share, directly owned. The option is immediately exercisable and expires on May 17, 2036.
BlossomHill Therapeutics, Inc. (BLSM) reports the initial beneficial ownership of director Sundeep Agrawal. He holds a Director Stock Option covering 10,671 shares of common stock at an exercise price of $6.28 per share, expiring on August 15, 2035, vesting in 12 equal monthly installments beginning on August 15, 2025. He is also reported as having indirect ownership of 578,524 underlying common shares through Series B Preferred Stock held by Brahma BlossomHill Partners, LLC, which is convertible into common stock on a 1-for-1 basis upon the closing of the company’s initial public offering, with no expiration date; Agrawal disclaims beneficial ownership of these indirect securities.
BlossomHill Therapeutics, Inc. (BLSM) had director Carl L. Gordon file an initial statement of beneficial ownership. The filing reports indirect holdings, through OrbiMed Private Investments VIII, LP, of Series A Preferred Stock and Series B Preferred Stock, together convertible into common stock on a 1-for-1 basis upon the closing of the company’s initial public offering, with no expiration date. Control and voting power over these securities are described as residing with OrbiMed entities, and members of the OrbiMed management committee, including Gordon, each disclaim beneficial ownership of the shares held by OrbiMed Private Investments VIII, LP.
BlossomHill Therapeutics, Inc. (BLSM) reported the initial beneficial ownership of certain Cormorant-managed investment funds and related entities. The filing lists indirect holdings of Series A Preferred Stock and Series B Preferred Stock, each share of which is convertible into 1 share of common stock upon the closing of the company’s initial public offering without further consideration, with no expiration date. The positions correspond to 1,599,993 underlying common shares from Series A and 1,701,541 underlying common shares from Series B. The interests are held through Cormorant Global Healthcare Master Fund, LP and several Cormorant Private Healthcare Funds, with Cormorant Asset Management, LP as investment manager and Bihua Chen as manager. Each reporting person disclaims beneficial ownership beyond its or her pecuniary interest.
BlossomHill Therapeutics, Inc. (BLSM) reported the initial equity holdings of General Counsel Vincent Paul Liptak. He holds 106,712 shares of Common Stock directly and an indirect position in Series B Preferred Stock through the Walter T. Liptak Revocable Trust, convertible into 22,687 shares of Common Stock upon the closing of the company’s initial public offering, with no expiration date. Liptak is a co-beneficiary and co-trustee of the trust and has voting and dispositive power over the trust-held securities.
BlossomHill Therapeutics, Inc. (BLSM) reported initial equity holdings for Chief Medical Officer Geoffrey Raymond Oxnard. He holds options immediately exercisable for 152,373 shares of common stock at an exercise price of $5.63 expiring January 2, 2035 and options for 34,031 shares at $6.28 expiring August 21, 2035, all held directly. He also directly holds 17,785 common shares. This filing reports existing positions and does not reflect any new purchases or sales.